San Diego-dependent Viking Therapeutics marked itself as a serious competitor during the weight loss drug market place in February right after revealing promising details from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection As well as in M